KR20170048426A - 시각 장애를 치료하기 위한 조성물 및 방법 - Google Patents

시각 장애를 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20170048426A
KR20170048426A KR1020177007882A KR20177007882A KR20170048426A KR 20170048426 A KR20170048426 A KR 20170048426A KR 1020177007882 A KR1020177007882 A KR 1020177007882A KR 20177007882 A KR20177007882 A KR 20177007882A KR 20170048426 A KR20170048426 A KR 20170048426A
Authority
KR
South Korea
Prior art keywords
lanosterol
ophthalmic
crystalline
lens
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177007882A
Other languages
English (en)
Korean (ko)
Inventor
캉 장
루이 호우
후이민 카이
Original Assignee
광저우 캉루이 바이오로지컬 파마슈티컬 테크놀로지 씨오., 엘티디.
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 광저우 캉루이 바이오로지컬 파마슈티컬 테크놀로지 씨오., 엘티디., 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 광저우 캉루이 바이오로지컬 파마슈티컬 테크놀로지 씨오., 엘티디.
Publication of KR20170048426A publication Critical patent/KR20170048426A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y10S514/912—

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
KR1020177007882A 2014-08-22 2015-08-24 시각 장애를 치료하기 위한 조성물 및 방법 Withdrawn KR20170048426A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462040721P 2014-08-22 2014-08-22
US62/040,721 2014-08-22
US201562194120P 2015-07-17 2015-07-17
US62/194,120 2015-07-17
PCT/US2015/046453 WO2016029199A1 (en) 2014-08-22 2015-08-24 Compositions and methods to treat vision disorders

Publications (1)

Publication Number Publication Date
KR20170048426A true KR20170048426A (ko) 2017-05-08

Family

ID=55351326

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177007882A Withdrawn KR20170048426A (ko) 2014-08-22 2015-08-24 시각 장애를 치료하기 위한 조성물 및 방법

Country Status (13)

Country Link
US (1) US10471076B2 (cg-RX-API-DMAC7.html)
EP (1) EP3182977B1 (cg-RX-API-DMAC7.html)
JP (1) JP6706020B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170048426A (cg-RX-API-DMAC7.html)
CN (2) CN111529481B (cg-RX-API-DMAC7.html)
AU (1) AU2015305199A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017003529A2 (cg-RX-API-DMAC7.html)
CA (1) CA2958868A1 (cg-RX-API-DMAC7.html)
EA (1) EA035798B1 (cg-RX-API-DMAC7.html)
HK (1) HK1243325A1 (cg-RX-API-DMAC7.html)
MX (1) MX2017002374A (cg-RX-API-DMAC7.html)
SG (1) SG11201701377YA (cg-RX-API-DMAC7.html)
WO (1) WO2016029199A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2958868A1 (en) 2014-08-22 2016-02-25 Guangzhou Kangrui Biological Pharmaceutical Technology Co., Ltd. Compositions and methods to treat vision disorders
WO2017019808A1 (en) * 2015-07-27 2017-02-02 Catacore, Inc Compositions for the treatment of cataracts
CN109364020B (zh) * 2015-09-02 2021-12-28 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
CN106344587A (zh) * 2016-08-24 2017-01-25 上海毕傲图生物科技有限公司 羊毛甾醇类化合物眼用制剂
CN107397745A (zh) * 2016-08-24 2017-11-28 上海毕傲图生物科技有限公司 唑类化合物眼用制剂
ES2890667T3 (es) * 2017-01-25 2022-01-21 Guangzhou Ocusun Ophthalmic Biotechnology Co Ltd Compuesto de profármaco de lanosterol y su uso del mismo
GB2581656A (en) * 2017-11-17 2020-08-26 Piraee Mahmood Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders
CN109985052A (zh) * 2017-12-29 2019-07-09 上海蓝木化工有限公司 三萜类化合物的新用途
US11872236B2 (en) 2018-04-05 2024-01-16 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases
JP7046266B2 (ja) * 2018-07-25 2022-04-01 グアンジョウ オクスン オフサルミク バイオテクノロジー カンパニーリミテッド ラノステロールプロドラッグ化合物の結晶形及びその使用
US12329763B2 (en) * 2019-03-04 2025-06-17 Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. Composition of lanosterol prodrug compound, preparation method therefor and use thereof
MX2021009520A (es) 2021-08-06 2023-02-07 Foodvica S A De C V Composicion oftalmica para el tratamiento de trastornos visuales.
CN115737654B (zh) 2021-09-03 2025-11-21 成都瑞沐生物医药科技有限公司 一种滴眼给药预防和/或治疗白内障的眼用制剂
CN116570706A (zh) * 2022-02-09 2023-08-11 上海瑞吉康生物医药有限公司 使用多肽治疗白内障的方法
WO2023198192A1 (zh) * 2022-04-15 2023-10-19 广州润尔眼科生物科技有限公司 甾体化合物在制备预防和/或治疗老花眼的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216106B2 (en) * 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
WO2005084208A2 (en) * 2004-02-27 2005-09-15 New York University A novel class of sterol ligands and their uses in regulation of cholesterol and gene expression
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
WO2009107753A1 (ja) * 2008-02-29 2009-09-03 財団法人 名古屋産業科学研究所 後眼部到達用リポソーム及び後眼部疾患用医薬組成物
RU2476226C2 (ru) * 2008-08-05 2013-02-27 Амазония Фитомедикаментос Лтда Фармацевтические применения ланоста-8,24-диен-3-олов
CA2878946A1 (en) * 2012-07-17 2014-01-23 Regents Of The University Of Michigan Non-surgical method of treatment for cataract
EP2890363A1 (en) * 2012-08-31 2015-07-08 Bausch & Lomb Incorporated Ophthalmic compositions with omega-3 fatty acids
CA2958868A1 (en) 2014-08-22 2016-02-25 Guangzhou Kangrui Biological Pharmaceutical Technology Co., Ltd. Compositions and methods to treat vision disorders

Also Published As

Publication number Publication date
JP6706020B2 (ja) 2020-06-03
HK1243325A1 (zh) 2018-07-13
US10471076B2 (en) 2019-11-12
EA201790397A1 (ru) 2017-08-31
CN111529481B (zh) 2023-09-15
JP2017525769A (ja) 2017-09-07
EP3182977A4 (en) 2018-04-11
MX2017002374A (es) 2017-09-15
SG11201701377YA (en) 2017-03-30
EA035798B1 (ru) 2020-08-12
CN107206009A (zh) 2017-09-26
WO2016029199A1 (en) 2016-02-25
BR112017003529A2 (pt) 2019-08-20
CN111529481A (zh) 2020-08-14
EP3182977A1 (en) 2017-06-28
AU2015305199A1 (en) 2017-04-13
CA2958868A1 (en) 2016-02-25
CN107206009B (zh) 2020-03-27
US20170065617A1 (en) 2017-03-09
EP3182977B1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
JP6706020B2 (ja) 視覚障害を処置する組成物と方法
JP6209791B2 (ja) 白内障を処置するためのα−クリスタリン凝集の阻害剤
US20190117675A1 (en) Compositions And Methods To Treat And/Or Prevent Vision Disorders Of The Lens Of The Eye
Zhao et al. Lanosterol reverses protein aggregation in cataracts
JP6482458B2 (ja) App特異性のbace(asbi)およびその使用
JP6796581B2 (ja) ミッシングタンパク質の小分子模倣体を用いた生理機能の回復
TW201805004A (zh) 用於預防具風險病患之阿茲海默症之㗁衍生物
US20200140500A1 (en) High throughput methods, protein inhibitors, and uses thereof
HK40011572A (en) Non-surgical method of treatment for cataract
CN117177742A (zh) 溶酶体相关膜蛋白靶向化合物及其用途
US20200138832A1 (en) Compounds and prodrugs thereof for the treatment of ophthalmic disease
HK1212271B (en) Inhibitors of alpha-crystallin aggregation for the treatment for cataract
HK1219691B (en) Pharmaceutical composition and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170322

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20190429

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid